Edmond DE Rothschild Holding S.A. Has $34.10 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Edmond DE Rothschild Holding S.A. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 255,186 shares of the life sciences company’s stock after selling 29,185 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Illumina were worth $34,101,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Cerity Partners LLC boosted its stake in shares of Illumina by 172.2% in the 3rd quarter. Cerity Partners LLC now owns 24,076 shares of the life sciences company’s stock valued at $3,140,000 after purchasing an additional 15,231 shares during the last quarter. Private Trust Co. NA boosted its stake in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares during the last quarter. FMR LLC grew its holdings in Illumina by 127.3% during the 3rd quarter. FMR LLC now owns 767,294 shares of the life sciences company’s stock worth $100,063,000 after acquiring an additional 429,723 shares during the period. Townsquare Capital LLC grew its holdings in Illumina by 28.1% during the 3rd quarter. Townsquare Capital LLC now owns 13,109 shares of the life sciences company’s stock worth $1,710,000 after acquiring an additional 2,872 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Illumina by 1.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,579 shares of the life sciences company’s stock valued at $9,987,000 after purchasing an additional 1,433 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ILMN. Stephens reaffirmed an “overweight” rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group reduced their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Performance

Shares of ILMN stock opened at $80.00 on Monday. The firm has a market cap of $12.67 billion, a PE ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 12 month low of $79.30 and a 12 month high of $156.66. The company’s fifty day simple moving average is $102.80 and its 200-day simple moving average is $126.82. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.